| 1 |
Strohl_2017 |
Current progress in innovative engineered antibodies |
Strohl, William R. |
2017 |
2017-08-18 |
COMM-USE |
N |
PMC5777977 |
28822103.0 |
10.1007/s13238-017-0457-8 |
la9svzml |
0.555735 |
Dove_2004 |
|
| 2 |
Rajeshkumar_2020 |
Fatal toxicity of chloroquine or hydroxychloroquine with metformin in mice |
N.V Rajeshkumar; Shinichi Yabuuchi; Shweta G. Pai; Anirban Maitra; Manuel Hidalgo; Chi V. Dang |
2020 |
2020-04-04 |
BioRxiv |
Y |
|
|
10.1101/2020.03.31.018556 |
zghh0zbd |
0.553316 |
Ekins_2015, Pastuch-Gawołek_2019, van_Boven_2008 |
Rolain_2007 |
| 3 |
Aslesh_2018 |
Skipping Multiple Exons to Treat DMD—Promises and Challenges |
Aslesh, Tejal; Maruyama, Rika; Yokota, Toshifumi |
2018 |
2018-01-02 |
COMM-USE |
N |
PMC5874658 |
29301272.0 |
10.3390/biomedicines6010001 |
mtmfh3uy |
0.461885 |
|
|
| 4 |
Brouillet_2010 |
Co-lethality studied as an asset against viral drug escape: the HIV protease case |
Brouillet, Sophie; Valere, Thomas; Ollivier, Emmanuelle; Marsan, Laurent; Vanet, Anne |
2010 |
2010-06-17 |
COMM-USE |
N |
PMC2898770 |
20565756.0 |
10.1186/1745-6150-5-40 |
s30p3a23 |
0.458305 |
|
Zhu_X_2015 |
| 5 |
Reichert_2006 |
Anti-infective monoclonal antibodies: perils and promise of development |
Reichert, Janice M.; Dewitz, Matthew C. |
2006 |
2006-01-01 |
PMC |
N |
PMC7097328 |
16518372.0 |
10.1038/nrd1987 |
cyjz29ot |
0.421188 |
Dove_2004 |
|
| 6 |
Thomas_2010 |
Receptor mimicry as novel therapeutic treatment for biothreat agents |
Thomas, Richard J |
2010 |
2010-01-01 |
None |
N |
PMC3035151 |
21327124.0 |
10.4161/bbug.1.1.10049 |
c7av3xql |
0.420714 |
|
Lee_C_2019, Opsenica_2011 |
| 7 |
Riaño-Umbarila_2019 |
Generation of a Broadly Cross-Neutralizing Antibody Fragment against Several Mexican Scorpion Venoms |
Riaño-Umbarila, Lidia; Gómez-Ramírez, Ilse V.; Ledezma-Candanoza, Luis M.; Olamendi-Portugal, Timoteo; Rodríguez-Rodríguez, Everardo Remi; Fernández-Taboada, Guillermo; Possani, Lourival D.; Becerril, Baltazar |
2019 |
2019-01-10 |
COMM-USE |
N |
PMC6356842 |
30634620.0 |
10.3390/toxins11010032 |
vk7dsy4r |
0.418238 |
|
|
| 8 |
Dove_2004 |
Making prevention pay |
Dove, Alan |
2004 |
2004-01-01 |
PMC |
N |
PMC7097210 |
15060549.0 |
10.1038/nbt0404-387 |
s6x0igia |
0.411178 |
|
|
| 9 |
Kramer_2015 |
Antilipidemic Drug Therapy Today and in the Future |
Kramer, Werner |
2015 |
2015-04-24 |
PMC |
N |
PMC7122375 |
26330256.0 |
10.1007/164_2015_15 |
7r35ow4y |
0.401856 |
Bumcrot_2006 |
|
| 10 |
Mathew_2015 |
Computational Docking Study of p7 Ion Channel from HCV Genotype 3 and Genotype 4 and Its Interaction with Natural Compounds |
Mathew, Shilu; Fatima, Kaneez; Fatmi, M. Qaiser; Archunan, Govindaraju; Ilyas, Muhammad; Begum, Nargis; Azhar, Esam; Damanhouri, Ghazi; Qadri, Ishtiaq |
2015 |
2015-06-01 |
COMM-USE |
N |
PMC4451521 |
26030803.0 |
10.1371/journal.pone.0126510 |
cxxk09t2 |
0.385385 |
|
Zhu_X_2015, Gao_M_2010 |
| 11 |
Gerold_2013 |
Opportunities and Risks of Host-targeting Antiviral Strategies for Hepatitis C |
Gerold, Gisa; Pietschmann, Thomas |
2013 |
2013-10-04 |
PMC |
N |
PMC7089091 |
|
10.1007/s11901-013-0187-1 |
lgae22f8 |
0.365659 |
Jerome_2005, Wisskirchen_2014 |
Lin_K_2013 |
| 12 |
Pawlotsky_2014 |
What are the pros and cons of the use of host-targeted agents against hepatitis C? |
Pawlotsky, Jean-Michel |
2014 |
2014-05-31 |
PMC |
N |
|
24583032.0 |
10.1016/j.antiviral.2014.02.008 |
px1xaszl |
0.363768 |
Shaw_2011 |
|
| 13 |
Prabakaran_2009 |
Combination Therapy Using Chimeric Monoclonal Antibodies Protects Mice from Lethal H5N1 Infection and Prevents Formation of Escape Mutants |
Prabakaran, Mookkan; Prabhu, Nayana; He, Fang; Hongliang, Qian; Ho, Hui-Ting; Qiang, Jia; TaoMeng,; Goutama, Michael; Kwang, Jimmy |
2009 |
2009-05-22 |
COMM-USE |
N |
PMC2682562 |
19478856.0 |
10.1371/journal.pone.0005672 |
cdm39qt9 |
0.354864 |
|
|
| 14 |
Saylor_2009 |
Monoclonal antibody-based therapies for microbial diseases |
Saylor, Carolyn; Dadachova, Ekaterina; Casadevall, Arturo |
2009 |
2009-12-30 |
None |
N |
PMC2810317 |
20006139.0 |
10.1016/j.vaccine.2009.09.105 |
40tq0fa7 |
0.350002 |
Dove_2004 |
Flego_2013 |
| 15 |
Van_Norman_2018 |
Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies |
Van Norman, Gail A. |
2018 |
2018-06-25 |
None |
N |
PMC6058931 |
30062226.0 |
10.1016/j.jacbts.2018.02.001 |
58ta20fg |
0.344437 |
Dove_2004 |
|
| 16 |
Hansson_2015 |
Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection |
Hansson, Magnus Joakim; Moss, Steven James; Bobardt, Michael; Chatterji, Udayan; Coates, Nigel; Garcia-Rivera, Jose A; Elmér, Eskil; Kendrew, Steve; Leyssen, Pieter; Neyts, Johan; Nur-E-Alam, Mohammad; Warneck, Tony; Wilkinson, Barrie; Gallay, Philippe; Gregory, Matthew Alan |
2015 |
2015-01-22 |
None |
N |
PMC4336584 |
25619934.0 |
10.1016/j.chembiol.2014.10.023 |
n9ptifg8 |
0.339165 |
|
Zhu_X_2015, Lee_C_2019 |
| 17 |
Adriouch_2011 |
Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer |
Adriouch, Sahil; Franck, Emilie; Drouot, Laurent; Bonneau, Carole; Jolinon, Nelly; Salvetti, Anna; Boyer, Olivier |
2011 |
2011-09-29 |
PMC |
N |
PMC3202221 |
22046170.0 |
10.3389/fmicb.2011.00199 |
psaf2vls |
0.331378 |
|
|
| 18 |
Bolken_2008 |
Discovery and development of antiviral drugs for biodefense: Experience of a small biotechnology company |
Bolken, Tove C.; Hruby, Dennis E. |
2008 |
2008-01-31 |
None |
N |
PMC2972676 |
17765333.0 |
10.1016/j.antiviral.2007.07.003 |
12kihnp7 |
0.317043 |
Dove_2004 |
Zhu_X_2015 |
| 19 |
Padberg_2015 |
2.6 Anti-infective Agents |
Padberg, Stephanie |
2015 |
2015-12-31 |
PMC |
N |
PMC7150338 |
|
10.1016/b978-0-12-408078-2.00007-x |
rtqkvf63 |
0.301302 |
|
|